Mount Sinai Hospital

TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting

Retrieved on: 
Friday, March 8, 2024

NEW YORK, March 08, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of data presentations highlighting data from the ULTIMATE I & II Phase 3 trials evaluating BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the upcoming American Academy of Neurology 2024 annual meeting, being held April 13 - 18, 2024, in Dever, Colorado.

Key Points: 
  • NEW YORK, March 08, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of data presentations highlighting data from the ULTIMATE I & II Phase 3 trials evaluating BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the upcoming American Academy of Neurology 2024 annual meeting, being held April 13 - 18, 2024, in Dever, Colorado.
  • Abstracts are now available online and can be accessed on the AAN meeting website at https://www.aan.com/msa/Public/Events/Index/49 .
  • Details of the upcoming presentations are outlined below.
  • Lead Author: Stephen Krieger, MD - The Corinne Goldsmith Dickinson Center for MS, The Mount Sinai Hospital NY, NY
    Lead Author: Derrick Robertson, MD - University of South Florida (USF) Morsani College of Medicine in Tampa, Florida
    Lead Author: Derrick Robertson, MD - University of South Florida (USF) Morsani College of Medicine in Tampa, Florida
    Following the presentations, the data presented will be available on the Publications page, located within the Pipeline section, of the Company’s website at www.tgtherapeutics.com/publications.cfm .

ByHeart Appoints Amy Schulman as Chair of the Board of Directors, Further Solidifying its Position as a Leader in the Infant Nutrition Category

Retrieved on: 
Tuesday, March 5, 2024

NEW YORK, March 5, 2024 /PRNewswire/ --Today, ByHeart, the next-generation baby nutrition company, announced the appointment of Amy Schulman, managing partner at Polaris partners, as Chair of the Board. A stalwart supporter of ByHeart since its inception, Schulman's designation signifies a pivotal moment for the company as it experiences momentous growth and solidifies its position as an industry leader.

Key Points: 
  • "Amy's insights and passion for health innovation and social impact align with ByHeart's mission," said ByHeart Co-Founder and CEO Ron Belldegrun.
  • "We chose Amy as the Chair because of her extensive track record in life sciences and infant nutrition.
  • "I have been a staunch supporter of ByHeart from its early days, and I am honored to now chair their board," said Schulman.
  • ByHeart remains dedicated to advancing infant nutrition through science, innovation and a commitment to excellence.

Belong.Life Goes All In on AI: Launches First-Ever Proactive Conversational AI Cancer Mentor, Setting New Standard in Personalized Patient Support

Retrieved on: 
Wednesday, February 28, 2024

NEW YORK, Feb. 28, 2024 /PRNewswire/ -- Belong.Life, a leading global provider of AI-powered patient education and support solutions, has unveiled the BelongAI Dave - Cancer Mentor app to bring the most advanced and comprehensive cancer support technology to patients and caregivers around the world. The new solution marks a significant step forward in personalized cancer support, by providing patients with a proactive and comprehensive conversational-AI solution for managing their journey 24/7.

Key Points: 
  • The new solution marks a significant step forward in personalized cancer support, by providing patients with a proactive and comprehensive conversational-AI solution for managing their journey 24/7.
  • Dave currently supports hundreds of thousands of cancer patients in the app and has generated exceptionally high levels of engagement.
  • In addition to providing direct patient support, the AI Cancer Mentor technology is available as a customizable patient support SaaS solution for health insurers, hospitals, and health systems.
  • "In addition to Dave's precision and personalized communications, his proactive capabilities represent a significant gamechanger in patient support.

New Case Series Demonstrates Potential of Aquadex Therapy for End-Stage Liver Disease Patients with Fluid Overload

Retrieved on: 
Tuesday, February 6, 2024

The publication, “Utilization of Aquapheresis Among Hospitalized Patients with End-Stage Liver Disease: A Case Series and Literature Review,” is a single-center retrospective case series featured in Clinical Transplantation .

Key Points: 
  • The publication, “Utilization of Aquapheresis Among Hospitalized Patients with End-Stage Liver Disease: A Case Series and Literature Review,” is a single-center retrospective case series featured in Clinical Transplantation .
  • The most common cause of liver disease was alcohol-related, with nine of the 14 patients presenting with alcohol-associated cirrhosis.
  • In this case series, Aquadex was shown to provide a potential additional solution to mitigate these clinical gaps.
  • Aquadex is proven to simply, safely, and precisely remove excess fluid from patients suffering from fluid overload who have not responded to conventional medical management, including diuretics.

Clinique Partners with Icahn School of Medicine at Mount Sinai to Establish the Mount Sinai-Clinique Healthy Skin Dermatology Center

Retrieved on: 
Friday, February 2, 2024

Clinique and Icahn School of Medicine at Mount Sinai today announced a philanthropic partnership to establish the Mount Sinai-Clinique Healthy Skin Dermatology Center.

Key Points: 
  • Clinique and Icahn School of Medicine at Mount Sinai today announced a philanthropic partnership to establish the Mount Sinai-Clinique Healthy Skin Dermatology Center.
  • Research conducted under the Mount Sinai-Clinique Healthy Skin Dermatology Center aims to uncover scientific findings to accelerate the creation of new topical and systemic treatments that help alleviate allergic skin conditions.
  • The priority is to bridge basic science with practical application in the clinic to improve people’s lives through healthy skin.
  • Dr. David Orentreich is Assistant Clinical Professor of Dermatology at Icahn Mount Sinai, and he and Dr. Catherine Orentreich are members of the Mount Sinai Dermatology Advisory Board.

Pulse Biosciences Announces Preliminary Findings from its CellFX nsPFA 360 Cardiac Catheter First-In-Human Feasibility Study to be Featured in Podium Presentation at the AF Symposium

Retrieved on: 
Wednesday, January 31, 2024

The session will include a presentation on the latest developments in Nanosecond Pulsed Field (nsPFA) technology, specifically highlighting the preliminary findings from the Company’s CellFX nsPFA 360 Cardiac Catheter First-In-Human Feasibility Study.

Key Points: 
  • The session will include a presentation on the latest developments in Nanosecond Pulsed Field (nsPFA) technology, specifically highlighting the preliminary findings from the Company’s CellFX nsPFA 360 Cardiac Catheter First-In-Human Feasibility Study.
  • "I look forward to presenting one of our initial cases with this promising technology at the AF Symposium and am honored to be part of the team to perform the first-in-human procedures with the CellFX nsPFA 360 Cardiac Catheter," said Dr. Vivek Reddy.
  • "The circumferential footprint and flexible structure of the 360 nsPFA catheter has been extremely fast and versatile in these initial procedures, setting it apart from many other PFA catheters.
  • We look forward to completing enrollment in this study to fully assess the safety and durability of this next generation PFA technology."

Face Expert Dr. Georges J. Samaha Joins Exclusive Haute Beauty Network

Retrieved on: 
Wednesday, January 31, 2024

NEW YORK, Jan. 31, 2024 /PRNewswire-PRWeb/ -- Dr. Georges Samaha is double-board certified by the American Board of Plastic Surgery. He is a diplomate of the American Board of Plastic Surgery as well as a diplomate of the American Board of Surgery. Dr. Samaha has specific interests in various aspects of facial plastic surgery — including deep plane facelift, neck lift, rhinoplasty, and eyelid rejuvenation — as well as breast and body contouring procedures. Patients travel from around the world for the above procedures including breast augmentation, breast lifts, high-definition tummy tucks, natural buttock augmentation using fat transfer known as the Brazilian Butt Lift ("BBL"), and his special natural high-definition liposuction with abdominal etching technique. Dr. Samaha's array of popular procedures can provide patients with beautiful, natural curves and are truly life-changing.

Key Points: 
  • Dr. Georges J. Samaha joins Haute Beauty Network as a face expert representing the Miami, FL market.
  • NEW YORK, Jan. 31, 2024 /PRNewswire-PRWeb/ -- Dr. Georges Samaha is double-board certified by the American Board of Plastic Surgery.
  • He is a diplomate of the American Board of Plastic Surgery as well as a diplomate of the American Board of Surgery.
  • Dr. Samaha has specific interests in various aspects of facial plastic surgery — including deep plane facelift, neck lift, rhinoplasty, and eyelid rejuvenation — as well as breast and body contouring procedures.

UNFO Introduces Innovative Corrective Foot Brace For Newborns, Elevating Pediatric Orthopedic Care In The U.S.

Retrieved on: 
Tuesday, January 16, 2024

TEL AVIV, Israel, Jan. 16, 2024 /PRNewswire/ -- UNFO Med Ltd., the manufacturer of the Universal Neonatal Foot Orthotics (UNFO) system, is thrilled to introduce a first of its kind corrective foot brace for the treatment of various foot conditions such as Metatarsus Adductus (MTA), a common condition in newborns that causes the front half of the foot, or forefoot, to turn inward. Other conditions include Metatarsus Varus, forefoot adduction, intoeing, and skew foot. This development marks a significant milestone in pediatric orthopedic care, replacing the need for casting and surgical intervention.

Key Points: 
  • This development marks a significant milestone in pediatric orthopedic care, replacing the need for casting and surgical intervention.
  • Metatarsus Adductus – also known as MTA – is a congenital foot condition that occurs in approximately 7% of births.
  • Following seven years of dedicated research, he unveiled UNFO, a short foot orthotic device worn below the ankle.
  • Dr. Daizade has treated over 15,000 patients with the UNFO brace and has had a 95% rate of success[1].

ENT and Allergy Associates, LLP Welcomes Otolaryngologist Usmaan Basharat, M.D. to its Renowned Team

Retrieved on: 
Monday, January 8, 2024

To continue this momentum, the practice proudly introduces its newest otolaryngologist, Usmaan Basharat, M.D.

Key Points: 
  • To continue this momentum, the practice proudly introduces its newest otolaryngologist, Usmaan Basharat, M.D.
  • who will join ENTA's Staten Island clinical location at 1 Teleport Drive on September 1, 2024.
  • Dr. Basharat’s expertise spans both pediatric and adult care, making him a valuable addition to the practice's commitment to comprehensive patient services.
  • Eager to further his commitment to healthcare, he then pursued his Medical Degree at the University of Arizona College of Medicine–Phoenix.

HeartSciences Announces Closing of License Agreements with the Icahn School of Medicine at Mount Sinai to Develop and Commercialize AI Cardiovascular Algorithms

Retrieved on: 
Monday, November 20, 2023

The closing of our licenses with Icahn Mount Sinai now propels us forward with our cardiovascular disease AI-ECG development programs.

Key Points: 
  • The closing of our licenses with Icahn Mount Sinai now propels us forward with our cardiovascular disease AI-ECG development programs.
  • The licenses from Icahn Mount Sinai grant rights to multiple patented and unpatented AI-based ECG/EKG algorithms and technologies for the screening and diagnosis of cardiovascular disease.
  • The AI cardiovascular algorithms are based on technology developed by Icahn Mount Sinai faculty and licensed by Mount Sinai to HeartSciences.
  • The financial interest of Mount Sinai faculty is pursuant to the Mount Sinai Intellectual Property Policy.